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839-5
Two Transgenic Animal Models Expressing Human Troponin T Gene Mutations: One Exhibiting Dilated Cardiomyopathy (W141) and the Other Exhibiting Hypertrophic Cardiomyopathy (Q92) Jasvinder Sidhu, Duanxiang Li, Zhinong Wang, A.J. Marian, Francesco J. DeMayo, George E. Taffet, Robert Roberts, Baylor College of Medicine, Houston, TX Background: The usual response of the heart is hypertrophy. Decompensation and subsequent heart failure often occurs after transition from hypertrophy to dilatation but appears to reflect an inhibition of growth. Troponin T (cTnT) mutations have been identified to cause familial hypertrophic cardiomyopathy (HCM) and others familial dilated cardiomyopathy (DCM). Thus, different mutations of the same gene induce different growth patterns. HCM is induced by cTnT Q92 and DCM by cTnT W141 mutations. Methods: We generated a transgenic mouse (TM) expressing the cTnT Q92 mutation with a phenotype of HCM and a TM expressing the cTnT W141 with a phenotype of DCM using alpha MHC as the cardiac specific promotor. Results: The HCM phenotype (cTnT Q92) has normal heart size with sarcomere disarray, fibrosis and an increased cardiac ejection rate 73.9 ± 9.4. In contrast, the DCM phenotype cTnT W141 has a large dilated heart without fibrosis but with decreased contractility. Echo analysis was normal at 4 weeks but at 12 weeks showed: Diastolic left ventricular dimension (LVD) in non-transgene (NT) was 3.68 + .06 versus 4.77 + .20 (p< .05) in TM; systolic LVD of 2.32 + .09 in NT versus 4.01 + .20 in TM; fractional shortening rate of NT was 0.37 + .01 versus 0.16 + .009 in TM; and peak ejection rate of 113 + 5 in NT versus 84 + 4 in TM. Gene microarray and northern analysis of myocardial gene expression in HCM and DCM were performed for markers associated with a hypertrophic growth response: Expression of IGF and ANP was normal in HCM and DCM. In contrast, skeletal alpha actin was decreased in HCM but increased in DCM. BNP normal in HCM was increased in DCM. GP130, increased in HCM was decreased 1 to 2 fold in DCM. Conclusion: GP130 a cytokine receptor claimed to be necessary for the hypertrophic growth response was down regulated in our DCM model and thus, may play a pivotal role in the lack of a hypertrophic growth response. Differential analysis of the GP130 pathway in the two models should determine whether this pathway is responsible for lack of the growth response in DCM.
11:45 a.m.
839-6 Role of Left Atrial Contractile Function in Functional Capacity of Patients With Hypertrophic Nonobstructive Cardiomyopathy
Yukitaka Shizukuda, Vandana Sachdev, Cynthia L. Brenneman, Charles W. Birdsall, Lameh Fananapazir, Jonathan F. Plehn, National Heart, Lung, and Blood Institute, Bethesda, MD Background: Left atrial (LA) dilatation and reduced atrial contractile function have been demonstrated in symptomatic patients with hypertrophic, non-obstructive cardiomyopathy (HNCM), suggesting the presence of a primary atrial myopathy. Since LA contractile function partially governs left ventricular (LV) preload reserve and maintenance of the Frank-Starling mechanism, LA systolic dysfunction could provide a mechanism for exercise intolerance in HNCM. We, therefore, evaluated LA contractile function in 50 patients with HNCM (mean age=37+10 years, 29 men/21 women) with normal LVEF (mean=69±6%) who were stratified for symptoms of congestive heart failure. Methods:
We analyzed LA volume normalized to body surface area, active atrial ejection fraction (LAEF), ejection force (LAF), and kinetic energy (LAKE), in asymptomatic (Group 1, n=19) and symptomatic (Group 2, n=31) subjects and compared these parameters to symptom-limited metabolic stress testing performed within one week of echocardiographic examination. Results: MRI-derived LV mass was similar between Groups 1 and 2 Background: Many patients with heart failure (HF) and a reduced ejection fraction (EF) have anemia. The prevalence and importance of anemia in patients with HF and a normal EF (diastolic HF) are not known. Thus, we hypothesize that anemia is common in diastolic HF and associated with a worse outcome.
Methods:
We evaluated 137 patients with clinical evidence of HF and a normal EF (> 0.50).
Results:
The age was 65±15 (mean ± SD) years, and 58% were women. Anemia (hemoglobin, Hb, < 12 gm/dl in women; < 13 gm/dl in men) was common, occurring in 45% of patients. Patients with and without anemia had similar ages (65±15 vs 65±14), EF (0.62±0.08 vs 0.61±0.07), LV mass (213±77 vs 193±85 gms), and systolic mitral annular velocity (6.8±1.5 vs 6.9±2.1 cm/sec). Patients with anemia had a higher brain natriuretic peptide (BNP) (322±330 vs 160±240 pg/ml, p<0.001), worse diastolic dysfunction grade by mitral Doppler (1.3±8 vs 0.8±7, p<0.001), and a higher ratio of peak mitral inflow velocity to mitral annular velocity (E/E M ) (13.5±6.5 vs 9.7±4.2, p<0.001) compared to patients without anemia. Reduced Hb concentration correlated with both elevated BNP (r 2 =0.15, p<0.0001) and E/E M (r 2 =0.15, p<0.0001). Patients with anemia had a reduced two-year cardiac hospitalization-free survival (hazard ratio 2.0, p<0.05) Conclusion: Anemia is common in pts with HF and a normal EF (diastolic HF) and is associated with greater elevations in BNP, more severe diastolic dysfunction, and a worse prognosis. Background: Anemia has been shown to be a risk factor for mortality in mild to moderate chronic heart failure (CHF), but its importance in severe CHF and its ability to predict hospitalization has not been defined.
Methods:
We evaluated the relationship between hemoglobin level and mortality and hospitalization in 2286 patients (1822 men, 464 women) with severe CHF enrolled in the COPERNICUS study. All enrolled patients had dyspnea or fatigue at rest or on minimal exertion for at least 2 months and a left ventricular ejection fraction <25%.
Results: There was a highly significant (P<0.0001) but small (r = -0.089) inverse relationship between baseline hemoglobin and creatinine levels. Patients with low hemoglobin were at significantly higher risk of a major clinical events, the magnitude of risk decreasing with increasing hemoglobin, both in univariate analyses (all P<0.001) and in multivariate analyses which adjusted for sex and other predictors of risk, including age, left ventricular ejection fraction, creatinine, body mass index, systolic blood pressure, CHF etiology and treatment with carvedilol (all P<0.01). Mean creatinine levels and one-year Kaplan-Meier event rates are shown below: Conclusion: Low hemoglobin is an independent risk factor for adverse outcomes in patients with severe HF. Whether correction of anemia improves outcomes in CHF warrants further study. 
